All In Biotech

Drug Trial Radar · NCT04948333

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Oct 13, 2021

Primary completion

Mar 12, 2024

Study completion Feb 25, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • ABL001 40mg BIDDrug

    One tablet of 40 mg will be taken orally twice a day (BID)

  • ABL001 80mg QDDrug

    Two tablets of 40 mg will be taken orally once a day (QD)

  • ABL001 200mg QDDrug

    Five tablets of 40 mg will be taken orally once a day (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at BaselineTime frame: Week 48

Locations

48 sites in 16 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Thessaloniki, Greece

  • Novartis Investigative Site

    Monza, MB, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Verona, VR, Italy

  • Novartis Investigative Site

    Johor Bahru, Malaysia

  • Novartis Investigative Site

    Kuala Selangor, Malaysia

  • Novartis Investigative Site

    George Town, Pulau Pinang, Malaysia

  • Novartis Investigative Site

    Kota Kinabalu, Sabah, Malaysia

  • Novartis Investigative Site

    Khoudh, Oman

  • Novartis Investigative Site

    Katowice, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Taegu, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.